@coffeecup33
The fact that MSB didn't immediately tell us about the details of the equity financing facility that had been offered to them tells us that there are probably unfavourable terms inside it and that if the details are immediately released, it would put more downward pressure on the already weak share price.
Maybe Silviu was hoping that after the initial drop post trading halt, the share price would rally back to a level above $1.92 before releasing the details of the financing facility. This way, he couldn't be accused of diluting existing holders by issuing new shares at near 10-year low levels.
If the terms of the financing facility are favourable to MSB or if there is nothing nasty to hide, why couldn't they just release the details at the same time as the announcement of Teva walking away?
It simply doesn't make sense.
- Forums
- ASX - By Stock
- MSB
- Over 3 weeks since the Halt , only 1/2 of Ann, SP heading further South, SI ??????
MSB
mesoblast limited
Add to My Watchlist
0.93%
!
$1.63

Over 3 weeks since the Halt , only 1/2 of Ann, SP heading further South, SI ??????, page-4
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.63 |
Change
0.015(0.93%) |
Mkt cap ! $2.082B |
Open | High | Low | Value | Volume |
$1.63 | $1.67 | $1.61 | $6.975M | 4.265M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 707 | $1.63 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.64 | 7320 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 11200 | 1.625 |
11 | 72699 | 1.620 |
1 | 30000 | 1.615 |
7 | 58298 | 1.610 |
3 | 96589 | 1.605 |
Price($) | Vol. | No. |
---|---|---|
1.635 | 7000 | 1 |
1.640 | 17668 | 3 |
1.645 | 7000 | 1 |
1.650 | 37309 | 4 |
1.655 | 40000 | 2 |
Last trade - 16.10pm 04/07/2025 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online